GLP-1 Agonists in Type 1 Diabetes Mellitus
- 1 June 2016
- journal article
- review article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 50 (8) , 656-665
Abstract
Objective: To review the use of GLP-1 agonists in patients with type 1 diabetes mellitus (T1DM). Data Sources: A search using the MEDLINE database, EMBASE, and Cochrane Database was performed through March 2016 using the search terms glucagon-like peptide 1 (GLP-1) agonists, incretin, liraglutide, exenatide, albiglutide, dulaglutide, type 1 diabetes mellitus. Study Selection and Data Extraction: All English-language trials that examined glycemic end points using GLP-1 agonists in humans with T1DM were included. Data Synthesis: A total of 9 clinical trials examining the use of GLP-1 agonists in T1DM were identified. On average, hemoglobin A 1C (A1C) was lower than baseline, with a maximal lowering of 0.6%. This effect was not significant when tested against a control group, with a relative decrease in A1C of 0.1% to 0.2%. In all trials examined, reported hypoglycemia was low, demonstrating no difference when compared with insulin monotherapy. Weight loss was seen in all trials, with a maximum weight loss of 6.4 kg over 24 weeks. Gastrointestinal adverse effects are potentially limiting, with a significant number of patients in trials reporting nausea. Conclusion: The use of GLP-1 agonists should be considered in T1DM patients who are overweight or obese and not at glycemic goals despite aggressive insulin therapy; however, tolerability of these agents is a potential concern. Liraglutide has the strongest evidence for use and would be the agent of choice for use in overweight or obese adult patients with uncontrolled T1DM.Keywords
This publication has 38 references indexed in Scilit:
- Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-upDiabetes Care, 2016
- 2. Classification and Diagnosis of DiabetesDiabetes Care, 2015
- The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: OverviewDiabetes Care, 2013
- GLP-1 agonists in type 1 diabetesClinical Immunology, 2013
- Type 1 Diabetes Treatment beyond Insulin: Role of GLP-1 AnalogsJournal of Investigative Medicine, 2013
- Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell FunctionDiabetes, 2011
- Temporal patterns in overweight and obesity in Type 1 diabetesDiabetic Medicine, 2010
- The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well‐beingDiabetes, Obesity and Metabolism, 2006
- Amylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year, randomized controlled trialDiabetic Medicine, 2004
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993